/Dexcom%20Inc%20HQ-by%20JHVEPhoto%20via%20Shutterstock.jpg)
Valued at a market cap of $25.5 billion, DexCom, Inc. (DXCM) is a medical device company that designs, develops, and commercializes continuous glucose monitoring (CGM) systems. The San Diego, California-based company’s products help patients, caregivers, and healthcare professionals manage diabetes and broader metabolic health conditions in real time. It is expected to announce its fiscal Q3 earnings for 2025 after the market closes on Thursday, Oct. 30.
Before this event, analysts expect this medical device company to report a profit of $0.57 per share, up 26.7% from $0.45 per share in the year-ago quarter. The company has surpassed Wall Street’s bottom-line estimates in two of the last four quarters, while missing on two other occasions. Its earnings of $0.48 per share in the previous quarter topped the consensus estimates by 6.7%.